Huang M, Page C, Reynolds RK, Lin J: Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 2000,79(1):67–73.PubMedCrossRef 14. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr: Stat3 as an oncogene. Cell 1999,98(3):295–303.PubMedCrossRef MLL inhibitor 15. Levy DE, Inghirami G: STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA 2006,103(27):10151–10152.PubMedCentralPubMedCrossRef 16. Huang S, Bucana CD, Van Arsdall M, Fidler IJ: Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 2002,21(16):2504–2512.PubMedCrossRef
17. Deng JY, Sun D, Liu XY, Pan Y, Liang H: STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol 2010,16(42):5380–5387.PubMedCentralPubMedCrossRef 18. Niu G, Wright KL,
Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al.: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002,21(13):2000–2008.PubMedCrossRef 19. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M: Activation of signal transducer and activator of transcription 3 in renal cell {Selleck Anti-cancer Compound Library|Selleck Anticancer Compound Library|Selleck Anti-cancer Compound Library|Selleck Anticancer Compound Library|Selleckchem Anti-cancer Compound Library|Selleckchem Anticancer Compound Library|Selleckchem Anti-cancer Compound Library|Selleckchem Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|buy Anti-cancer Compound Library|Anti-cancer Compound Library ic50|Anti-cancer Compound Library price|Anti-cancer Compound Library cost|Anti-cancer Compound Library solubility dmso|Anti-cancer Compound Library purchase|Anti-cancer Compound Library manufacturer|Anti-cancer Compound Library research buy|Anti-cancer Compound Library order|Anti-cancer Compound Library mouse|Anti-cancer Compound Library chemical structure|Anti-cancer Compound Library mw|Anti-cancer Compound Library molecular weight|Anti-cancer Compound Library datasheet|Anti-cancer Compound Library supplier|Anti-cancer Compound Library in vitro|Anti-cancer Compound Library cell line|Anti-cancer Compound Library concentration|Anti-cancer Compound Library nmr|Anti-cancer Compound Library in vivo|Anti-cancer Compound Library clinical trial|Anti-cancer Compound Library cell assay|Anti-cancer Compound Library screening|Anti-cancer Compound Library high throughput|buy Anticancer Compound Library|Anticancer Compound Library ic50|Anticancer Compound Library price|Anticancer Compound Library cost|Anticancer Compound Library solubility dmso|Anticancer Compound Library purchase|Anticancer Compound Library manufacturer|Anticancer Compound Library research buy|Anticancer Compound Library order|Anticancer Compound Library chemical structure|Anticancer Compound Library datasheet|Anticancer Compound Library supplier|Anticancer Compound Library in vitro|Anticancer Compound Library cell line|Anticancer Compound Library concentration|Anticancer Compound Library clinical trial|Anticancer Compound Library cell assay|Anticancer Compound Library screening|Anticancer Compound Library high throughput|Anti-cancer Compound high throughput screening| carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 2002,168(2):762–765.PubMedCrossRef 20. Chang KC, Wu MH, Jones D, Chen FF, Tseng YL: Racecadotril Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour. J Pathol 2006,210(2):224–233.PubMedCrossRef 21. David D, Rajappan LM, Balachandran K, Thulaseedharan JV, Nair AS, Pillai RM: Prognostic significance of STAT3 and phosphorylated STAT3 in human soft tissue tumors – a clinicopathological analysis. J Exp Clin Cancer Res 2011, 30:56.PubMedCentralPubMedCrossRef 22.
Hunter CA: New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005,5(7):521–531.PubMedCrossRef 23. Leonard WJ, O’Shea JJ: Jaks and STATs: biological implications. Annu Rev Immunol 1998, 16:293–322.PubMedCrossRef 24. Hay ED: The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 2005,233(3):706–720.PubMedCrossRef 25. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW: Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 2007,213(2):374–383.PubMedCrossRef 26. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL, et al.: Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 2006,12(18):5369–5376.PubMedCrossRef 27. Ho MY, Leu SJ, Sun GH, Tao MH, Tang SJ, Sun KH: IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol 2009,183(10):6217–6226.PubMedCrossRef 28.